



Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy?

Submitted by Emmanuel Lemoine on Fri, 07/18/2014 - 13:53

Titre	Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy?
Type de publication	Article de revue
Auteur	Tran, Van-Thanh [1], Benoît, Jean-Pierre [2], Venier-Julienne, Marie-Claire [3]
Editeur	Elsevier
Type	Article scientifique dans une revue à comité de lecture
Année	2011
Langue	Anglais
Date	04/04/2011
Numéro	1-2
Pagination	1-11
Volume	407
Titre de la revue	International Journal of Pharmaceutics
ISSN	1873-3476
Mots-clés	Delayed-Action Preparations [4], Drug Delivery Systems [5], Microspheres [6], Particle Size [7], Pharmaceutical Preparations/administration and dosage [8], Polymers/chemistry [9]
Résumé en anglais	Drug delivery via biodegradable microparticles benefits from both the protection of the encapsulated drug from hazardous conditions and the controlled release of the encapsulated drug, thereby reducing the administration frequency and improving patient compliance. Microsphere-size particle distribution is considered as being an important factor that affects the choice of the administration route and the drug-release rate. Significant research efforts have been directed towards the production of monodispersed "designer" particles. Amongst various techniques, some have been examined from lab-scale to industrial-scale. This review provides a global overview of monodispersed microparticle production methods and then focuses on recent processes being used to produce biodegradable microparticles applied in the pharmaceutical field. Further discussion about the choice of process according to the microparticle objectives of use is suggested.
URL de la notice	http://okina.univ-angers.fr/publications/ua3671 [10]
DOI	10.1016/j.ijpharm.2011.01.027 [11]

Liens

[1] [http://okina.univ-angers.fr/publications?f\[author\]=23553](http://okina.univ-angers.fr/publications?f[author]=23553)

[2] <http://okina.univ-angers.fr/j.benoit/publications>

[3] <http://okina.univ-angers.fr/ma.venier/publications>

[4] [http://okina.univ-angers.fr/publications?f\[keyword\]=7831](http://okina.univ-angers.fr/publications?f[keyword]=7831)

- [5] [http://okina.univ-angers.fr/publications?f\[keyword\]=7832](http://okina.univ-angers.fr/publications?f[keyword]=7832)
- [6] [http://okina.univ-angers.fr/publications?f\[keyword\]=7833](http://okina.univ-angers.fr/publications?f[keyword]=7833)
- [7] [http://okina.univ-angers.fr/publications?f\[keyword\]=5232](http://okina.univ-angers.fr/publications?f[keyword]=5232)
- [8] [http://okina.univ-angers.fr/publications?f\[keyword\]=7834](http://okina.univ-angers.fr/publications?f[keyword]=7834)
- [9] [http://okina.univ-angers.fr/publications?f\[keyword\]=7835](http://okina.univ-angers.fr/publications?f[keyword]=7835)
- [10] <http://okina.univ-angers.fr/publications/ua3671>
- [11] <http://dx.doi.org/10.1016/j.ijpharm.2011.01.027>

Publié sur *Okina* (<http://okina.univ-angers.fr>)